Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 7/20 | 0.56 |
| ▸ | KDR | P35968 | 5/20 | 0.51 |
| ▸ | FLT1 | P17948 | 3/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | FLT4 | P35916 | 2/20 | 0.51 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.49 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | MAPK7 | Q13164 | 3/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5430434 | 0.90 | ENPP1 (0.54) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL5214519 | 0.89 | ENPP1 (0.52) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL4377475 | 0.86 | EGFR (0.64) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL6415927 | 0.86 | ENPP1 (0.54) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL3129523 | 0.83 | EGFR (0.56) | ENPP1EGFREPHB4ERBB2 | |
| SCHEMBL4087511 | 0.83 | EGFR (0.56) | ENPP1EGFREPHB4ERBB2 | |
| SCHEMBL3928120 | 0.83 | ENPP1 (0.57) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL5438862 | 0.82 | ENPP1 (0.52) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL5433323 | 0.82 | ENPP1 (0.52) | ENPP1KDRFLT1EGFRFGFR1 | |
| SCHEMBL17179600 | 0.80 | EPHA2 (0.52) | ENPP1KDRFLT1EGFRFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | ASTRAZENCA (SE) | 2007-02-01 | — | — | US | disclosed |
| EP-1653965-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | Astrazeneca AB (SE) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005013998-A1 | QUINAZOLINE DERIVATIVES AS INHIBITORS OF VEGF RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027145-A1 | Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases | FLT4, FLT1, VEGFA | ENPP1 2940/4885KDR 4/4885FLT1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.